CRC Site Operations Blueprint: A Practical Guide to Running a Compliant Site

Running a compliant clinical research site is never just about paperwork. It is about building systems — repeatable, defensible processes that hold up whether you are managing one study or twelve, whether the monitor arrives on a scheduled visit or an FDA inspector walks through the door unannounced. For Clinical Research Coordinators, site operations is the unglamorous core of the job: delegation logs, training records, patient retention strategies, source documentation discipline, and the thousand small decisions that either protect participants or expose a site to findings.

This guide is written for working CRCs who need practical, actionable guidance, not a regulatory textbook. Each section covers a core operational area, explains the regulatory basis for why it matters, and gives you a concrete approach you can implement or improve today. All references link directly to primary sources, including the finalized ICH E6(R3) Good Clinical Practice guideline, which became the current standard in January 2025.

Why Site Operations Matter More Than Ever in 2026

FDA oversight of clinical research sites is continuous and active. The FDA's Bioresearch Monitoring (BIMO) Program conducts over 1,000 on-site inspections and data audits annually, targeting clinical investigators, IRBs, sponsors, and CROs across all of FDA's product centers. The program was established specifically to assure the quality and integrity of data submitted in support of new product approvals, and to protect the rights and welfare of human subjects in FDA-regulated research.

At the same time, ICH finalized E6(R3) on January 6, 2025, the most significant revision to Good Clinical Practice guidelines since 1996. The new guideline introduces a risk-proportionate, quality-by-design framework that requires sites to demonstrate that their processes are genuinely fit-for-purpose, not just checkbox-compliant. The EMA set an effective date of July 23, 2025 for E6(R3)'s overarching principles and Annex 1. The FDA published its own E6(R3) guidance document in September 2025.

For CRCs, this means the bar for "good enough" has been raised. Processes that sailed through monitoring visits under E6(R2) may now face closer scrutiny. The following sections provide a practical playbook for each core operations domain.

The Delegation of Authority Log: Your Most-Audited Document

The Delegation of Authority (DOA) log — sometimes called the Delegation of Duties log or Site Signature and Delegation Log — establishes who is authorized to do what on your study. It is one of the first documents a monitor or FDA inspector will request, and one of the most consistently cited sources of inspection findings across all site types.

The requirement comes directly from ICH GCP. Section 4.1.5 of E6(R2) (carried into E6(R3)) requires the investigator to maintain a list of appropriately qualified persons to whom significant trial-related duties have been delegated. The FDA's official guidance Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects clarifies that the investigator must ensure any individual to whom a task is delegated is qualified by education, training, and experience, and remains fully accountable even after delegation.

What the DOA Log Must Contain

At minimum, a compliant DOA log must include each staff member's full legal name printed legibly; their signature and initials as they will appear on all study documents; their specific role on the study; a clear list of study tasks they are authorized to perform; the start date of their authorization, which must not precede their protocol training completion date; the PI's dated initials confirming each authorization; and an end date (initialed and dated by the PI) when a staff member leaves the study or their role changes.

Practical DOA Log Management

The DOA log is a living document and must be treated as such. Build a standing procedure: any time a new team member is added to a study, their onboarding sequence ends, not begins, with the PI initialing their DOA line. Training must be complete, CVs filed, and GCP certification current before the PI authorizes. If a staff member's role changes mid-study, close the current line with an end date and open a new line with updated tasks. As the ICH E6(R3) guideline makes clear, tasks delegated must align with each individual's education, training, experience, and professional qualifications, not just their availability.

One practical tip worth implementing immediately: keep a laminated quick-reference card clipped to the front of your study binder listing the task codes from your delegation log template. When staff changes happen under time pressure, having the codes visible prevents errors in task assignment that create downstream audit findings.

Staff Training: Documenting Before Day One

Training documentation is where sites are most likely to create a paper trail that contradicts itself. The rule is straightforward: no study-related task may be performed until the person completing it has been trained on it and that training has been documented. This applies to GCP training, protocol-specific training, and any procedure-level training required by the protocol or sponsor's manual.

GCP Training Requirements

While FDA's Code of Federal Regulations does not use the exact phrase "GCP training," the requirement flows from 21 CFR Part 312 and ICH GCP — investigators and staff must be qualified by education, training, and experience to perform their assigned tasks. Completed GCP training certification is the industry-accepted evidence of that qualification and what FDA inspectors will look for. NIH/NIAID's site personnel guidance requires current GCP training for all study personnel, with certificates maintained in the trial master file. Since January 2017, the NIH has mandated GCP training for all investigators and staff conducting NIH-funded clinical trials — without a valid certificate, participation in federally funded studies is prohibited.

GCP training must be current. Most sponsors and CROs require recertification every two to three years. Check your sponsor's protocol or site initiation documents for their specific requirement. NIH/NIAID's site personnel qualifications guidance also notes that some sponsors participate in mutual recognition programs that allow a single GCP training certificate to be accepted across multiple sponsors — worth confirming with your individual sponsors.

Protocol-Specific Training

GCP training is necessary but not sufficient. Every staff member must also be trained on the specific protocol they are working under before their first study-related activity. Protocol training typically occurs at or immediately after the Site Initiation Visit (SIV) and must be documented in the study-specific training log, which is maintained in the Investigator Site File. The training log should record the date of training, the version of the protocol covered, the materials reviewed, and the trainer's name and signature.

Patient Recruitment and Retention: The Operational Core

Enrollment is where studies succeed or fail. Sites that consistently under-enroll lose studies, lose sponsor relationships, and eventually lose the resources that sustain research infrastructure. Retention — keeping enrolled participants engaged through study completion — is equally critical. Lost participants generate protocol deviations, missing data, and compromised study integrity.

Recruitment Systems That Work

Effective recruitment is a process, not an improvisation. The sites that consistently meet enrollment targets have built a structured identification-to-screening pipeline before the first patient is approached. That pipeline includes a screening log that tracks every patient assessed for eligibility, not just those enrolled, a clear referral pathway with the clinical care team, and a standard process for how potential participants are identified and contacted.

Maintain a screen failure log from day one. It is a regulatory requirement — your ISF must document patients screened but not enrolled, but it is also operationally valuable. Patterns in screen failures often reveal a fixable process issue. If 60% of your screen failures trace to the same exclusion criterion, that is worth a conversation with the sponsor about whether outreach materials can better pre-screen for that factor before patients come in.

Retention Strategies That Hold Up Under Scrutiny

Retention is both an ethical obligation and an operational one. A participant who withdraws mid-study may trigger a protocol deviation if their withdrawal creates a missed assessment window within required visit windows. The following retention practices are used by high-performing research sites and are consistent with GCP's emphasis on participant welfare:

• Visit reminders with adequate lead time. A reminder call 48 to 72 hours before a visit, followed by a same-day confirmation, significantly reduces no-shows. Document that reminder contacts occurred, but never record personal health information discussed informally in study source documents.
• Clear expectations set at the consent visit. Participants who genuinely understood what the study would require before they signed are far less likely to withdraw when those demands materialize. The informed consent process is your first and most important retention tool.
• Practical barriers addressed proactively. Transportation, parking, and scheduling inflexibility are among the most common reasons participants drop out of trials. Where your protocol and sponsor permit, build flexibility into the scheduling process before a participant misses their first visit, not after.
• Consistent, genuine communication between visits. Participants who feel like research partners stay in studies longer than those who feel like data points. A brief check-in call between scheduled visits, or a simple thank-you after a difficult procedure visit, makes a measurable difference in retention rates.

Monitoring Visit Readiness: A Daily Mindset, Not a Pre-Visit Sprint

Sites that scramble to prepare for monitoring visits are sites whose ongoing compliance has slipped. The goal of inspection readiness is not to sprint before a visit: it is to maintain a state where a monitoring visit confirms what you already know about your site's status rather than discovering problems you did not know existed.

What the Monitor Is Looking For

A CRA conducting a monitoring visit is verifying three things above all others: that the data in the case report form (CRF) matches the source documents, that the ISF is complete and current, and that IP accountability records reconcile without gaps. Under 21 CFR Part 312 and ICH GCP, investigators are required to maintain adequate records of the administration of the investigational drug to subjects, and to permit FDA inspection and copying of those records at any time.

The 72-Hour Pre-Visit Checklist

In the 72 hours before a scheduled monitoring visit, work through the following:

• Verify the DOA log is current, all active staff have open delegation lines, all departed staff have PI-initialed end dates.
• Confirm your IRB approval has not lapsed and will not lapse before the next renewal. Check the expiration date on your current approval letter.
• Reconcile IP accountability records. Use the Drug Accountability Calculator to confirm every unit received traces to a current disposition — dispensed, on hand, or returned and destroyed.
• Pull source documents for your three most recent study participants and cross-check against CRF data entries. Every recorded value should match; every required assessment should be documented.
• Confirm your current protocol version and ICF version in the ISF match what your site is actively using.
• Brief your study team: who is the monitor, when do they arrive, what are they reviewing, and what is your team's role during the visit.

ALCOA+ Quality Control: The Standard Behind Every Entry

ALCOA is the foundational data quality framework in clinical research, articulated by the FDA and embedded throughout ICH GCP E6(R3). It stands for Attributable, Legible, Contemporaneous, Original, and Accurate. The extended version, ALCOA+, adds Complete, Consistent, Enduring, and Available.

These nine attributes are not aspirational ideals. They are the criteria an auditor or inspector applies to every entry in your source documents. A single entry that fails ALCOA+ standards can generate a monitoring finding. Systemic failures across entries can generate a Form 483 observation or, in severe cases, a warning letter citation.

What Each ALCOA+ Attribute Requires in Practice

• Attributable: Every entry traces to the specific person who made it. Use your initials exactly as they appear on the DOA log. Never make an entry under someone else's credentials, and never allow anyone else to make entries under yours.
• Legible: Handwritten entries can be read clearly by any reviewer. If a monitor has to ask what a word says, it is a finding in progress.
• Contemporaneous: Entries are made at the time the event occurs, not reconstructed hours or days later from memory. Back-dating or forward-dating entries is data fraud, not merely a GCP deviation.
• Original: Source data is the first recording of an observation. A transcribed value from a paper form into an electronic system does not replace the original paper form; the original must be retained.
• Accurate: The recorded value is the actual value observed or measured. Do not round, estimate, or modify without following your protocol's correction procedures.
• Complete: All required fields are filled in. A blank field in a required CRF section is a data query. A pattern of blank fields is a systematic finding.
• Consistent: The same information recorded in two places matches. The date of a visit recorded in your source document matches the date in the CRF, the enrollment log, and the IP dispensing record.
• Enduring: Records are stored in a manner that preserves them for the required retention period, at a minimum, two years after the last marketing approval for which the data were submitted, or at least 15 years for IND studies under 21 CFR Part 312.62. Never destroy study records without written sponsor authorization and confirmation that retention requirements have been met.
• Available: Records can be located and produced for inspection when requested. "I can't find it" is not an acceptable response during a BIMO inspection.

Common FDA BIMO Findings and How to Prevent Them

The FDA's Bioresearch Monitoring Program conducts inspections specifically targeting clinical investigators, IRBs, sponsors, and CROs. The FDA's own published BIMO inspection metrics, released annually, document recurring findings across fiscal years: inadequate subject protection and informed consent issues, failure to follow the investigational plan, inadequate drug accountability records, and failure to maintain adequate and accurate case histories are among the most consistent citations.

The most common site-level findings fall into five categories. Notably, none of these are exotic or hard-to-anticipate failures. They are all systemic process gaps that disciplined site operations can prevent:

• Informed consent deficiencies. Participants enrolled using a consent form that was not the currently approved IRB version; consent obtained by staff not listed on the DOA log as authorized to consent; consent forms missing required elements per FDA investigator responsibilities guidance; re-consent not completed after a protocol amendment required it.
• Protocol deviations not reported. The deviation itself is often less serious than the failure to report it. Unreported deviations to the sponsor and IRB within required timeframes are among the most consistent findings across BIMO inspections.
• IP accountability gaps. Missing documentation for IP dispensed; temperature excursions not assessed and reported to the sponsor; drug accountability records that do not reconcile to zero at study closeout. Use the IP Compliance Calculator to monitor accountability in real time.
• Inadequate source documentation. Assessments transcribed into the CRF without a corresponding primary source document; assessments reconstructed after the fact; corrections made by complete redaction of original entries rather than a single line-through preserving legibility.
• Delegation and training failures. Staff performing study tasks for which they have no authorized DOA log entry; training log dates that postdate the first study activity performed by that staff member.

Daily Habits That Keep a Site Inspection-Ready Year-Round

Inspection readiness is a daily practice, not a pre-visit project. The sites that perform well in monitoring visits and FDA inspections have built compliance into the routine of every study day. The following habits, practiced consistently, make the difference between a site that dreads visits and one that welcomes them as validation of what it already knows.

• End every patient visit with a documentation review. Before closing a visit record, verify all required assessments are documented, all source-to-CRF data matches, and any deviations are noted in real time. This takes five minutes with fresh memory. It takes significantly longer, and introduces errors, when reconstructed days later.
• Check IRB approval expiration dates monthly. Set a recurring calendar reminder. A lapsed approval requires all study activities to stop until renewal is obtained, an outcome that is always preventable with adequate advance notice.
• Reconcile IP weekly. Do not wait for a monitoring visit to discover a discrepancy in drug accountability records. A brief weekly count and reconciliation against your dispensing log prevents errors from compounding over months.
• Update the DOA log the same day staff changes occur. The day someone joins or leaves the study team is the day the log is updated, not at the next available moment.
• Document deviations in real time. When something does not go according to protocol — a missed visit window, an incorrect dose, a consent timing gap — document it immediately with a description of what occurred, why, and what corrective action was taken. Proactive deviation documentation is the mark of the quality culture ICH E6(R3) calls for. Late deviation documentation with incomplete context is a finding.
• Conduct quarterly self-audits. Set aside 30 minutes each quarter to walk through your ISF against ICH GCP E6(R3) Appendix C and your sponsor's essential document checklist. Gaps caught in a self-audit are correctable. The same gaps found by a monitor or inspector are findings.

A well-run clinical research site is one where compliance is woven into the workflow, not applied as a layer of preparation before someone external comes to check. CRCs who build that discipline become the coordinators that sponsors want to work with, site managers want to promote, and auditors have nothing to cite. The practical tools on this site, from the IP compliance calculator to the visit window calculator — exist to support that discipline at the level of daily operations.